Poseida Therapeutics Inc
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $2.19
- Today's High:
- $2.305
- Open Price:
- $2.23
- 52W Low:
- $1.54
- 52W High:
- $8.82
- Prev. Close:
- $2.23
- Volume:
- 325555
Company Statistics
- Market Cap.:
- $201.63 million
- Book Value:
- 1.557
- Revenue TTM:
- $156.71 million
- Operating Margin TTM:
- -18.39%
- Gross Profit TTM:
- $-22407000
- Profit Margin:
- -18.64%
- Return on Assets TTM:
- -7.4%
- Return on Equity TTM:
- -29.05%
Company Profile
Poseida Therapeutics Inc had its IPO on 2020-07-10 under the ticker symbol PSTX.
The company operates in the Healthcare sector and Biotechnology industry. Poseida Therapeutics Inc has a staff strength of 348 employees.
Stock update
Shares of Poseida Therapeutics Inc opened at $2.23 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $2.19 - $2.31, and closed at $2.2.
This is a -1.35% slip from the previous day's closing price.
A total volume of 325,555 shares were traded at the close of the day’s session.
In the last one week, shares of Poseida Therapeutics Inc have increased by +3.77%.
Poseida Therapeutics Inc's Key Ratios
Poseida Therapeutics Inc has a market cap of $201.63 million, indicating a price to book ratio of 2.2648 and a price to sales ratio of 3.5246.
In the last 12-months Poseida Therapeutics Inc’s revenue was $156.71 million with a gross profit of $-22407000 and an EBITDA of $-23375000. The EBITDA ratio measures Poseida Therapeutics Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Poseida Therapeutics Inc’s operating margin was -18.39% while its return on assets stood at -7.4% with a return of equity of -29.05%.
In Q2, Poseida Therapeutics Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 641.2%.
Poseida Therapeutics Inc’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 0
- PEG
Its diluted EPS in the last 12-months stands at $-0.05 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Poseida Therapeutics Inc’s profitability.
Poseida Therapeutics Inc stock is trading at a EV to sales ratio of 1.9881 and a EV to EBITDA ratio of -16.1021. Its price to sales ratio in the trailing 12-months stood at 3.5246.
Poseida Therapeutics Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $281.22 million
- Total Liabilities
- $49.89 million
- Operating Cash Flow
- $43.07 million
- Capital Expenditure
- $1.18 million
- Dividend Payout Ratio
- 0%
Poseida Therapeutics Inc ended 2024 with $281.22 million in total assets and $0 in total liabilities. Its intangible assets were valued at $281.22 million while shareholder equity stood at $135.30 million.
Poseida Therapeutics Inc ended 2024 with $8.46 million in deferred long-term liabilities, $49.89 million in other current liabilities, 9000.00 in common stock, $-537164000.00 in retained earnings and $4.23 million in goodwill. Its cash balance stood at $49.91 million and cash and short-term investments were $214.61 million. The company’s total short-term debt was $5,863,000 while long-term debt stood at $58.40 million.
Poseida Therapeutics Inc’s total current assets stands at $230.20 million while long-term investments were $0 and short-term investments were $164.70 million. Its net receivables were $11.91 million compared to accounts payable of $2.10 million and inventory worth $0.
In 2024, Poseida Therapeutics Inc's operating cash flow was $43.07 million while its capital expenditure stood at $1.18 million.
Comparatively, Poseida Therapeutics Inc paid $0 in dividends in 2024.
Other key metrics
- Current Trading Price
- $2.2
- 52-Week High
- $8.82
- 52-Week Low
- $1.54
- Analyst Target Price
- $11.8
Poseida Therapeutics Inc stock is currently trading at $2.2 per share. It touched a 52-week high of $8.82 and a 52-week low of $8.82. Analysts tracking the stock have a 12-month average target price of $11.8.
Its 50-day moving average was $2.09 and 200-day moving average was $3.84 The short ratio stood at 2.71 indicating a short percent outstanding of 0%.
Around 2826% of the company’s stock are held by insiders while 5231.8% are held by institutions.
Frequently Asked Questions About Poseida Therapeutics Inc
Similar Industry Stocks (Biotechnology)
Most Active
Top Gainers
Top Losers
About
Poseida Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for patients with high unmet medical needs. The company develops P-PSMA-ALLO1, an autologous chimeric antigen receptor T cell (CAR-T) product candidate that is in Phase I trial for the treatment of patients with metastatic castrate resistant prostate cancer (mCRPC). It is also developing P-BCMA-ALLO1, which is in Phase I trial to treat patients with relapsed/refractory multiple myeloma; and P-MUC1C-ALLO1 that is in Phase I trial for treating a range of solid tumors, including breast, colorectal, lung, ovarian, pancreatic, and renal cancers. In addition, the company engages in the development of P-CD19CD20-ALLO1 for B cell malignancies and other autoimmune diseases; and P-BCMACD19-ALLO1, an allogeneic, off-the-shelf CAR-T product candidate in preclinical development for multiple myeloma. Further, it is developing P-PSMA-101, an allogeneic CAR-T product candidate for treating mCRPC. Additionally, the company engages in the development of P-OTC-101, a liver-directed gene therapy for the in vivo treatment of ornithine transcarbamylase deficiency; P-FVIII-101, a clinical stage liver-directed gene therapy for the in vivo treatment of hemophilia A; and P-PAH-101, a liver-directed gene therapy for the in vivo treatment of phenylketonuria. Poseida Therapeutics, Inc. has a research collaboration and license agreement with Takeda Pharmaceuticals USA, Inc., F. Hoffmann-La Roche Ltd, and Hoffmann-La Roche Inc. The company was incorporated in 2014 and is headquartered in San Diego, California.